420 related articles for article (PubMed ID: 32531895)
1. MnTBAP Reverses Pulmonary Vascular Remodeling and Improves Cardiac Function in Experimentally Induced Pulmonary Arterial Hypertension.
Gomez-Puerto MC; Sun XQ; Schalij I; Orriols M; Pan X; Szulcek R; Goumans MJ; Bogaard HJ; Zhou Q; Ten Dijke P
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32531895
[TBL] [Abstract][Full Text] [Related]
2. Autophagy contributes to BMP type 2 receptor degradation and development of pulmonary arterial hypertension.
Gomez-Puerto MC; van Zuijen I; Huang CJ; Szulcek R; Pan X; van Dinther MA; Kurakula K; Wiesmeijer CC; Goumans MJ; Bogaard HJ; Morrell NW; Rana AA; Ten Dijke P
J Pathol; 2019 Nov; 249(3):356-367. PubMed ID: 31257577
[TBL] [Abstract][Full Text] [Related]
3. Increased MAO-A Activity Promotes Progression of Pulmonary Arterial Hypertension.
Sun XQ; Peters EL; Schalij I; Axelsen JB; Andersen S; Kurakula K; Gomez-Puerto MC; Szulcek R; Pan X; da Silva Goncalves Bos D; Schiepers REJ; Andersen A; Goumans MJ; Vonk Noordegraaf A; van der Laarse WJ; de Man FS; Bogaard HJ
Am J Respir Cell Mol Biol; 2021 Mar; 64(3):331-343. PubMed ID: 33264068
[TBL] [Abstract][Full Text] [Related]
4. Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension.
Rol N; de Raaf MA; Sun XQ; Kuiper VP; da Silva Gonçalves Bos D; Happé C; Kurakula K; Dickhoff C; Thuillet R; Tu L; Guignabert C; Schalij I; Lodder K; Pan X; Herrmann FE; van Nieuw Amerongen GP; Koolwijk P; Vonk-Noordegraaf A; de Man FS; Wollin L; Goumans MJ; Szulcek R; Bogaard HJ
Cardiovasc Res; 2019 Feb; 115(2):432-439. PubMed ID: 30032282
[TBL] [Abstract][Full Text] [Related]
5. Combination Therapy with STAT3 Inhibitor Enhances SERCA2a-Induced BMPR2 Expression and Inhibits Pulmonary Arterial Hypertension.
Bisserier M; Katz MG; Bueno-Beti C; Brojakowska A; Zhang S; Gubara S; Kohlbrenner E; Fazal S; Fargnoli A; Dorfmuller P; Humbert M; Hata A; Goukassian DA; Sassi Y; Hadri L
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502015
[TBL] [Abstract][Full Text] [Related]
6. PPARγ-p53-Mediated Vasculoregenerative Program to Reverse Pulmonary Hypertension.
Hennigs JK; Cao A; Li CG; Shi M; Mienert J; Miyagawa K; Körbelin J; Marciano DP; Chen PI; Roughley M; Elliott MV; Harper RL; Bill MA; Chappell J; Moonen JR; Diebold I; Wang L; Snyder MP; Rabinovitch M
Circ Res; 2021 Feb; 128(3):401-418. PubMed ID: 33322916
[TBL] [Abstract][Full Text] [Related]
7. Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation.
Tian W; Jiang X; Sung YK; Shuffle E; Wu TH; Kao PN; Tu AB; Dorfmüller P; Cao A; Wang L; Peng G; Kim Y; Zhang P; Chappell J; Pasupneti S; Dahms P; Maguire P; Chaib H; Zamanian R; Peters-Golden M; Snyder MP; Voelkel NF; Humbert M; Rabinovitch M; Nicolls MR
Circulation; 2019 Oct; 140(17):1409-1425. PubMed ID: 31462075
[TBL] [Abstract][Full Text] [Related]
8. Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension.
Van der Feen DE; Kurakula K; Tremblay E; Boucherat O; Bossers GPL; Szulcek R; Bourgeois A; Lampron MC; Habbout K; Martineau S; Paulin R; Kulikowski E; Jahagirdar R; Schalij I; Bogaard HJ; Bartelds B; Provencher S; Berger RMF; Bonnet S; Goumans MJ
Am J Respir Crit Care Med; 2019 Oct; 200(7):910-920. PubMed ID: 31042405
[No Abstract] [Full Text] [Related]
9. BMPR2-expressing bone marrow-derived endothelial-like progenitor cells alleviate pulmonary arterial hypertension in vivo.
Harper RL; Maiolo S; Ward RJ; Seyfang J; Cockshell MP; Bonder CS; Reynolds PN
Respirology; 2019 Nov; 24(11):1095-1103. PubMed ID: 30977250
[TBL] [Abstract][Full Text] [Related]
10. CCL5 deficiency rescues pulmonary vascular dysfunction, and reverses pulmonary hypertension via caveolin-1-dependent BMPR2 activation.
Nie X; Tan J; Dai Y; Liu Y; Zou J; Sun J; Ye S; Shen C; Fan L; Chen J; Bian JS
J Mol Cell Cardiol; 2018 Mar; 116():41-56. PubMed ID: 29374556
[TBL] [Abstract][Full Text] [Related]
11. BMP type II receptor as a therapeutic target in pulmonary arterial hypertension.
Orriols M; Gomez-Puerto MC; Ten Dijke P
Cell Mol Life Sci; 2017 Aug; 74(16):2979-2995. PubMed ID: 28447104
[TBL] [Abstract][Full Text] [Related]
12. Paeoniflorin Ameliorates Chronic Hypoxia/SU5416-Induced Pulmonary Arterial Hypertension by Inhibiting Endothelial-to-Mesenchymal Transition.
Yu M; Peng L; Liu P; Yang M; Zhou H; Ding Y; Wang J; Huang W; Tan Q; Wang Y; Xie W; Kong H; Wang H
Drug Des Devel Ther; 2020; 14():1191-1202. PubMed ID: 32256050
[TBL] [Abstract][Full Text] [Related]
13. Regulation of mitochondrial fragmentation in microvascular endothelial cells isolated from the SU5416/hypoxia model of pulmonary arterial hypertension.
Suresh K; Servinsky L; Jiang H; Bigham Z; Zaldumbide J; Huetsch JC; Kliment C; Acoba MG; Kirsch BJ; Claypool SM; Le A; Damarla M; Shimoda LA
Am J Physiol Lung Cell Mol Physiol; 2019 Nov; 317(5):L639-L652. PubMed ID: 31461316
[TBL] [Abstract][Full Text] [Related]
14. Metformin Prevents Progression of Experimental Pulmonary Hypertension via Inhibition of Autophagy and Activation of Adenosine Monophosphate-Activated Protein Kinase.
Liu Y; Xu Y; Zhu J; Li H; Zhang J; Yang G; Sun Z
J Vasc Res; 2019; 56(3):117-128. PubMed ID: 31085922
[TBL] [Abstract][Full Text] [Related]
15. The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats.
Honda Y; Kosugi K; Fuchikami C; Kuramoto K; Numakura Y; Kuwano K
PLoS One; 2020; 15(10):e0240692. PubMed ID: 33057388
[TBL] [Abstract][Full Text] [Related]
16. Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension.
Chaumais MC; Djessas MRA; Thuillet R; Cumont A; Tu L; Hebert G; Gaignard P; Huertas A; Savale L; Humbert M; Guignabert C
Cardiovasc Res; 2021 Apr; 117(5):1391-1401. PubMed ID: 32653925
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel alleviates monocrotaline-induced pulmonary arterial hypertension via inhibition of FoxO1-mediated autophagy.
Feng W; Wang J; Yan X; Zhai C; Shi W; Wang Q; Zhang Q; Li M
Naunyn Schmiedebergs Arch Pharmacol; 2019 May; 392(5):605-613. PubMed ID: 30683943
[TBL] [Abstract][Full Text] [Related]
18. Berberine attenuates hypoxia-induced pulmonary arterial hypertension via bone morphogenetic protein and transforming growth factor-β signaling.
Chen M; Shen H; Zhu L; Yang H; Ye P; Liu P; Gu Y; Chen S
J Cell Physiol; 2019 Aug; 234(10):17482-17493. PubMed ID: 30786011
[TBL] [Abstract][Full Text] [Related]
19. The BMP Receptor 2 in Pulmonary Arterial Hypertension: When and Where the Animal Model Matches the Patient.
Happé C; Kurakula K; Sun XQ; da Silva Goncalves Bos D; Rol N; Guignabert C; Tu L; Schalij I; Wiesmeijer KC; Tura-Ceide O; Vonk Noordegraaf A; de Man FS; Bogaard HJ; Goumans MJ
Cells; 2020 Jun; 9(6):. PubMed ID: 32521690
[No Abstract] [Full Text] [Related]
20. HMGB1/TLR4 promotes hypoxic pulmonary hypertension via suppressing BMPR2 signaling.
Wang J; Tian XT; Peng Z; Li WQ; Cao YY; Li Y; Li XH
Vascul Pharmacol; 2019 Jun; 117():35-44. PubMed ID: 30610955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
